Skip to main content

Advertisement

Table 1 Enrolled patients characteristics

From: Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Study group   Patients
Breast cancer Adenocarcinoma 20
47,5
Median age (range)   (32–69)
Clinical status IIA 1
IIB 3
IIIA 12
IIIB 3
IIIC 1
Histologic grade 1 1
2 8
3 11
HER2 status positive 9
negative 11
ER status positive 11
negative 8
unknown 1
PR status positive 13
negative 7